Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Deferred Taxes (2023 - 2025)

Protalix BioTherapeutics (PLX) has 3 years of Deferred Taxes data on record, last reported at $59000.0 in Q3 2025.

  • For Q3 2025, Deferred Taxes fell 86.68% year-over-year to $59000.0; the TTM value through Sep 2025 reached $177000.0, down 25.0%, while the annual FY2024 figure was $236000.0, 107.63% up from the prior year.
  • Deferred Taxes reached $59000.0 in Q3 2025 per PLX's latest filing, down from $231000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $443000.0 in Q3 2024 and bottomed at -$3.1 million in Q2 2023.
  • Average Deferred Taxes over 3 years is -$334875.0, with a median of -$15500.0 recorded in 2023.
  • Peak YoY movement for Deferred Taxes: surged 1065.79% in 2024, then plummeted 86.68% in 2025.
  • A 3-year view of Deferred Taxes shows it stood at $38000.0 in 2023, then soared by 1065.79% to $443000.0 in 2024, then tumbled by 86.68% to $59000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $59000.0 in Q3 2025, $231000.0 in Q2 2025, and -$113000.0 in Q1 2025.